Overview

Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is an open clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of an add-on therapy with DLBS3233 in improving blood glucose control, lipid profile, and adiponectin in subjects with type-2 diabetes mellitus.
Phase:
Phase 3
Details
Lead Sponsor:
Dexa Medica Group